Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2026)

Sarepta Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $198.5 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 3.39% year-over-year to $198.5 million in Q1 2026; TTM through Mar 2026 was $198.5 million, a 3.39% decrease from a year earlier, with the FY2025 full-year figure at $199.4 million, up 3.59% from the prior year.
• Operating Leases was little changed at $198.5 million in Q1 2026 per SRPT's latest filing, from $199.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $215.0 million in Q3 2025 and bottomed at $35.2 million in Q3 2022.
• The 5-year median for Operating Leases is $141.0 million (2023), against an average of $135.8 million.
• Across the five-year window, Operating Leases slumped 44.46% in 2022 and jumped 282.5% in 2023, its largest moves.
• Year by year, Operating Leases stood at $57.6 million in 2022, then jumped by 144.82% to $141.0 million in 2023, then jumped by 36.54% to $192.5 million in 2024, then gained by 3.59% to $199.4 million in 2025, then decreased by 0.44% to $198.5 million in 2026.
• Per Business Quant, the three latest SRPT Operating Leases figures stand at $198.5 million (Q1 2026), $199.4 million (Q4 2025), and $215.0 million (Q3 2025).